We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

BioVie (NASDAQ:BIVI) Stock Drifts Higher on Fading Momentum From Its Parkinson's Data

● BioVie shares have added another leg to a volatile August, rising to $2.14, up 9.74%, on relativeVolumeof just 0.08, a small fraction of the frenzied turnover the stock saw earlier in the month.

Nitish Kishor | 25 August 2026

BioStem Technologies (NASDAQ:BSEM) Stock Drifts Higher Weeks After Its Nasdaq Uplisting

● BioStem Technologies shares have pushed higher, closing up 10.73% at $3.92, on relativeVolumeof roughly 0.76 times the stock's norm, meaning fewer shares changed hands than on an average session.

Nitish Kishor | 25 August 2026

Alvotech (NASDAQ:ALVO) Stock Rallies Past a Revenue Miss on the Strength of Its FDA Pipeline

● Alvotech shares have climbed to close near $5.25, up 18.51%, lifting the IcelandicBiosimilarsdeveloper'sMarket Valueback toward $2.05 billion, by far the largest company among recent speculative movers.

Nitish Kishor | 25 August 2026

Labcorp Holdings Inc. (NYSE:LH) Stock Hits 52-Week High Today

Headquartered in Burlington, North Carolina, Labcorp Holdings operates through Diagnostics Laboratories and Biopharma Laboratory Services segments, serving clients in approximately 100 countries. The company's nearly 71,000 employees supported more than 85 percent of new drugs and therapeutic products approved by the FDA in 2025 …

Nitish Kishor | 24 August 2026

Heartflow, Inc. (NASDAQ:HTFL) Stock Hits 52-Week High Today

Headquartered in Redwood City, California, Heartflow is a medical technology company focused on transforming coronary artery disease diagnosis through artificial intelligence and computational fluid dynamics. The company's flagship Heartflow Analysis creates patient-specific 3D models of coronary arteries from standard CT scans, allowing clinicians to …

Nitish Kishor | 24 August 2026

AtriCure, Inc. (NASDAQ:ATRC) Stock Hits 52-Week High Today

Headquartered in Broomfield, Colorado, AtriCure develops and commercializes solutions for the surgical treatment of atrial fibrillation. The company's flagship AtriCure System includes radiofrequency ablation devices used during cardiac surgery, while the AtriClip device is a surgically implanted left atrial appendage exclusion device that reduces …

Nitish Kishor | 24 August 2026

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Stock Hits 52-Week High Today

Headquartered in Atlanta, Georgia, Aveanna Healthcare provides home health, hospice, private duty nursing, and medical staffing solutions through three divisions across 403 locations in 39 states. The company's strategy centers on optimizing reimbursement through preferred payer relationships, pursuing strategic acquisitions, and targeting the growing …

Nitish Kishor | 24 August 2026

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Hits 52-Week High Today

Headquartered in San Diego, California, Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare endocrine diseases and endocrine-related tumors. The company's lead asset, PALSONIFY, is an oral somatostatin receptor type 2 agonist approved for treating acromegaly, offering a convenient alternative to injectable standard-of-care …

Nitish Kishor | 24 August 2026

Why Is Alvotech (NASDAQ:ALVO) Stock Up 19% Today?

Alvotech (NASDAQ:ALVO) shares are trading up 19.07% today at $5.28, as fresh bullish analyst coverage compounds momentum from last week's biosimilar licensing agreement with Lotus Pharmaceutical. The move builds on a stock that has already been trending higher over the past several sessions.

Vinay Lochav | 24 August 2026

Why Is Kura Oncology (NASDAQ:KURA) Rising Today?

Kura Oncology, Inc. (NASDAQ:KURA) shares rose in Monday's session as bullish analyst commentary reinforced confidence in the commercial launch of KOMZIFTI (ziftomenib). Citizens reiterated a Market Outperform rating with a $24 price target, citing strong early launch progress in relapsed and refractory NPM1-mutant acute …

Vinay Lochav | 24 August 2026
Support

Hi! How can we help you today?

Loading…